|
Nov 2
|
Syndax Pharmaceuticals Inc (SNDX) Reports Q3 2023 Financial Results
|
|
Nov 2
|
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
|
|
Nov 2
|
Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
|
|
Nov 2
|
Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
|
|
May 24
|
Syndax Announces Participation at Two Upcoming Investor Conferences
|